Vol. 2 No. 9 (2022): September
Reimbursement Recommendations

Tepotinib (Tepmetko)

Published September 12, 2022

Key Messages

  • CADTH recommends that Tepmetko not be reimbursed by public drug plans for the treatment of locally advanced unresectable or metastatic non–small cell lung cancer (NSCLC) harbouring MET tyrosine kinase receptor exon 14 (METex14) skipping alterations.
  • The clinical evidence reviewed by CADTH was not strong enough to show whether treatment with Tepmetko benefits patients with locally advanced or metastatic NSCLC harbouring METex14 skipping alterations. It is not known if Tepmetko would lead to better outcomes for patients compared to treatments that are currently available.
  • Patients identified a need for treatments that stop or slow the progression of disease, prolong life, promote independence, improve symptoms and quality of life (QoL), and have minimal side effects. It is not clear whether Tepmetko meets these needs.